• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Mutation Spectrum and Genotype-Phenotype Analyses in a Pakistani Cohort With Hemophilia B.巴基斯坦B型血友病队列中的突变谱及基因型-表型分析
Clin Appl Thromb Hemost. 2018 Jul;24(5):741-748. doi: 10.1177/1076029617721011. Epub 2017 Jul 28.
2
Assessment of the F9 genotype-specific FIX inhibitor risks and characterisation of 10 novel severe F9 defects in the first molecular series of Argentinian patients with haemophilia B.评估 F9 基因型特异性 FIX 抑制剂风险,并在首个阿根廷血友病 B 患者分子系列中鉴定 10 种新型严重 F9 缺陷。
Thromb Haemost. 2013 Jan;109(1):24-33. doi: 10.1160/TH12-05-0302. Epub 2012 Oct 23.
3
Comprehensive analysis of phenotypes and genetics in 21 Chinese families with haemophilia B: characterization of five novel mutations.对21个中国乙型血友病家庭的表型和遗传学进行综合分析:鉴定出五个新突变
Haemophilia. 2014 Nov;20(6):859-65. doi: 10.1111/hae.12534. Epub 2014 Sep 23.
4
An integrated multitool analysis contributes elements to interpreting unclassified factor IX missense variants associated with hemophilia B.综合多工具分析为解释与乙型血友病相关的未分类因子 IX 错义变异体提供了元素。
J Thromb Haemost. 2024 Oct;22(10):2724-2738. doi: 10.1016/j.jtha.2024.07.008. Epub 2024 Jul 15.
5
The characteristics and spectrum of F9 mutations in Chinese sporadic haemophilia B pedigrees.中国散发性血友病 B 家系中 F9 基因突变的特征和谱。
Haemophilia. 2019 Mar;25(2):316-323. doi: 10.1111/hae.13681. Epub 2019 Jan 16.
6
Molecular genotyping of the Italian cohort of patients with hemophilia B.意大利B型血友病患者队列的分子基因分型
Haematologica. 2005 May;90(5):635-42.
7
A novel missense mutation in F9 gene causes hemophilia B in a family with clinical variability.F9基因中的一种新型错义突变在一个具有临床变异性的家族中导致了B型血友病。
Blood Coagul Fibrinolysis. 2020 Mar;31(2):121-126. doi: 10.1097/MBC.0000000000000884.
8
Molecular characterization of 16 hemophilia B families in Aragon, Spain.
Blood Coagul Fibrinolysis. 2013 Sep;24(6):625-32. doi: 10.1097/MBC.0b013e3283610366.
9
Spectrum of F9 mutations in Chinese haemophilia B patients: identification of 20 novel mutations.中国血友病 B 患者 F9 基因突变谱:20 种新突变的鉴定。
Pathology. 2012 Jun;44(4):342-7. doi: 10.1097/PAT.0b013e328353443d.
10
Efficient detection of factor IX mutations by denaturing high-performance liquid chromatography in Taiwanese hemophilia B patients, and the identification of two novel mutations.应用变性高效液相色谱法对台湾血友病B患者进行IX因子突变的高效检测及两种新突变的鉴定
Kaohsiung J Med Sci. 2014 Apr;30(4):187-93. doi: 10.1016/j.kjms.2013.12.003. Epub 2014 Jan 6.

引用本文的文献

1
Clinical analysis and quality of life survey of hemophilia B patients in the central and western regions of China.中国中西部地区乙型血友病患者的临床分析与生活质量调查
Front Pediatr. 2024 May 9;12:1366990. doi: 10.3389/fped.2024.1366990. eCollection 2024.
2
Clinical Analysis and Mental Health Survey of Hemophilia Carriers: a Cross-sectional Study.血友病携带者的临床分析与心理健康调查:一项横断面研究。
Curr Med Sci. 2024 Apr;44(2):435-440. doi: 10.1007/s11596-024-2855-5. Epub 2024 Apr 2.
3
Investigation of the Bleeding Tendency in Sudanese Female Carriers of Hemophilia B.苏丹血友病 B 女性携带者出血倾向的调查。
Biomed Res Int. 2022 Jun 22;2022:6756130. doi: 10.1155/2022/6756130. eCollection 2022.
4
Defining the molecular pathology and consequent phenotypes in Egyptian HB patients.明确埃及乙肝患者的分子病理学及相应表型。
J Genet Eng Biotechnol. 2021 May 17;19(1):75. doi: 10.1186/s43141-021-00165-8.
5
Molecular characterization of hemophilia B patients in Colombia.哥伦比亚血友病 B 患者的分子特征。
Mol Genet Genomic Med. 2020 May;8(5):e1210. doi: 10.1002/mgg3.1210. Epub 2020 Mar 10.

本文引用的文献

1
Enhancing protein stability with extended disulfide bonds.利用延长的二硫键增强蛋白质稳定性。
Proc Natl Acad Sci U S A. 2016 May 24;113(21):5910-5. doi: 10.1073/pnas.1605363113. Epub 2016 May 9.
2
Mutation analysis of Swedish haemophilia B families - high frequency of unique mutations.瑞典B型血友病家族的突变分析——独特突变的高频率
Haemophilia. 2016 May;22(3):440-5. doi: 10.1111/hae.12854. Epub 2015 Nov 27.
3
The I-TASSER Suite: protein structure and function prediction.I-TASSER套件:蛋白质结构与功能预测
Nat Methods. 2015 Jan;12(1):7-8. doi: 10.1038/nmeth.3213.
4
The CDC Hemophilia B mutation project mutation list: a new online resource.美国疾病预防控制中心乙型血友病突变项目突变列表:一个新的在线资源。
Mol Genet Genomic Med. 2013 Nov;1(4):238-45. doi: 10.1002/mgg3.30. Epub 2013 Aug 19.
5
Clinical use of factor VIII and factor IX concentrates.凝血因子VIII和凝血因子IX浓缩物的临床应用。
Blood Transfus. 2013 Sep;11 Suppl 4(Suppl 4):s55-63. doi: 10.2450/2013.010s.
6
Organizing principles of mammalian nonsense-mediated mRNA decay.哺乳动物无意义介导的 mRNA 降解的组织原则。
Annu Rev Genet. 2013;47:139-65. doi: 10.1146/annurev-genet-111212-133424.
7
The Human Gene Mutation Database: building a comprehensive mutation repository for clinical and molecular genetics, diagnostic testing and personalized genomic medicine.人类基因突变数据库:为临床和分子遗传学、诊断测试以及个性化基因组医学构建全面的基因突变知识库。
Hum Genet. 2014 Jan;133(1):1-9. doi: 10.1007/s00439-013-1358-4.
8
An interactive mutation database for human coagulation factor IX provides novel insights into the phenotypes and genetics of hemophilia B.一个用于人类凝血因子 IX 的交互式突变数据库,为血友病 B 的表型和遗传学提供了新的见解。
J Thromb Haemost. 2013 Jul;11(7):1329-40. doi: 10.1111/jth.12276.
9
Evaluation of transfusion-related complications along with estimation of inhibitors in patients with hemophilia: A pilot study from a single center.血友病患者输血相关并发症的评估及抑制剂的测定:一项单中心的初步研究
Asian J Transfus Sci. 2013 Jan;7(1):8-10. doi: 10.4103/0973-6247.106714.
10
Outcome in moderate haemophilia.中度血友病的结局。
Blood Transfus. 2014 Jan;12 Suppl 1(Suppl 1):s330-6. doi: 10.2450/2012.0091-12. Epub 2012 Nov 20.

巴基斯坦B型血友病队列中的突变谱及基因型-表型分析

Mutation Spectrum and Genotype-Phenotype Analyses in a Pakistani Cohort With Hemophilia B.

作者信息

Khan Muhammad Tariq Masood, Naz Arshi, Ahmed Jawad, Shamsi Tahir, Ahmed Shariq, Ahmed Nisar, Imran Ayisha, Farooq Nazish, Khan Muhammad Tariq Hamayun, Taj Abid Sohail

机构信息

1 Hematology Department, Institute of Basic Medical Sciences, Khyber Medical University, Peshawar, Pakistan.

2 National Institute of Blood Diseases & Bone Marrow Transplantation, Karachi, Pakistan.

出版信息

Clin Appl Thromb Hemost. 2018 Jul;24(5):741-748. doi: 10.1177/1076029617721011. Epub 2017 Jul 28.

DOI:10.1177/1076029617721011
PMID:28752769
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6714882/
Abstract

This study aimed to (1) identify F9 genetic alterations in patients with hemophilia B (HB) of Pakistani origin and (2) determine the genotype-phenotype relationships in these patients. Diagnosed cases of HB were identified through registries at designated tertiary health-care centers across the country. Consenting patients were enrolled into the study. The factor IX (FIX) coagulation activity (FIX:C) and key clinical features were recorded. Direct sequencing of F9 was carried out in all patients. All the variants identified were analyzed for functional consequences employing in silico analysis tools. Accession numbers from National Center of Biotechnology Information ClinVar database were retrieved for the novel variants. Genotype-FIX:C relationships were determined followed by FIX:C clinical phenotype assessment. A total of 52 patients with HB from 36 unrelated families were identified, which mainly comprised patients with moderate HB (n = 35; 67.3%). Among these, 35 patients from 22 unrelated families could be contacted and enrolled into the study. Missense variants were the most frequent (58.8%), followed by nonsense variants (17.6%). A missense, a short insertion, and a nonsense novel variants in exon 2, 6, and 7, respectively, were also identified. The disease manifested FIX:C heterogeneity in relation to the corresponding mutation in a significant number of cases. Clinical phenotype heterogeneity was also observed in relation to FIX:C-based severity assessment. We concluded that the registered FIX-deficient population of Pakistan mainly comprises moderate HB. F9 mutation spectrum in Pakistani patients with HB is heterogeneous. The HB population of Pakistan manifests a significant amount of genotype-FIX:C and FIX:C-clinical phenotype heterogeneities.

摘要

本研究旨在

(1)鉴定巴基斯坦裔B型血友病(HB)患者的F9基因改变;(2)确定这些患者的基因型-表型关系。通过全国指定三级医疗中心的登记处识别出确诊的HB病例。同意参与的患者被纳入研究。记录了凝血因子IX(FIX)的凝血活性(FIX:C)和关键临床特征。对所有患者进行F9基因的直接测序。使用计算机分析工具对鉴定出的所有变异进行功能后果分析。从美国国立生物技术信息中心ClinVar数据库检索新变异的登录号。确定基因型与FIX:C的关系,随后进行FIX:C临床表型评估。共识别出36个无关家庭的52例HB患者,其中主要为中度HB患者(n = 35;67.3%)。其中,来自22个无关家庭的35例患者能够被联系并纳入研究。错义变异最为常见(58.8%),其次是无义变异(17.6%)。还分别在第2、6和7外显子中鉴定出1个错义、1个短插入和1个无义新变异。在大量病例中,疾病表现出与相应突变相关的FIX:C异质性。在基于FIX:C的严重程度评估方面也观察到临床表型异质性。我们得出结论,巴基斯坦登记的FIX缺乏人群主要为中度HB。巴基斯坦HB患者的F9突变谱具有异质性。巴基斯坦的HB人群表现出大量的基因型-FIX:C和FIX:C-临床表型异质性。